The proposed takeover of Shire PLC by Japans Takeda Pharmaceutical Company Ltd has received conditional clearance from the European Commission.
The companies have agreed to sell SHP647 an inflammatory bowel disease treatment Shire is developing along with some associated rights to help ease concerns about an overlap in similar drugs, including Takedas biggest-seller Entyvio.
However, the divestment is not a condition to completing the deal.
The sale of the drug was proposed by Takeda in talks with the EU, as announced in October.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Takeda has already secured unconditional clearance from regulators in the US, Japan, China and Brazil for the US$62bn deal to buy the British drugmaker.
The acquisition is expected to be completed on January 8, subject to shareholder approval.
Date: November 26, 2018
Source: MarketScreener